We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+17.37%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$120M
AUM Growth
+$9.25M
(+8.3%)
Cap. Flow
-$7.62M
Cap. Flow
% of AUM
-6.34%
Top 10 Holdings %
Top 10 Hldgs %
65.43%
Holding
37
New
9
Increased
9
Reduced
5
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LENZ
LENZ Therapeutics
LENZ
|
+$9.34M |
| 2 |
CMPS
Compass Pathways
CMPS
|
+$5.59M |
| 3 |
Replimune Group
REPL
|
+$4.61M |
| 4 |
SLNO
Soleno Therapeutics
SLNO
|
+$4.37M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$3.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$12.4M |
| 2 |
Axsome Therapeutics
AXSM
|
+$8.41M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$6.57M |
| 4 |
Trevi Therapeutics
TRVI
|
+$4.32M |
| 5 |
CG Oncology
CGON
|
+$3.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Axsome Therapeutics
AXSM
$12.4B
| – | – |
-72,113
| Closed | -$8.41M |
|
|
BPMC
27
DELISTED
Blueprint Medicines
BPMC
| – | – |
-74,192
| Closed | -$6.57M |
|
|
28
CG Oncology
CGON
$6.27B
| – | – |
-132,298
| Closed | -$3.24M |
|
29
Context Therapeutics
CNTX
$54.4M
| – | – |
-1,157,448
| Closed | -$708K |
|
30
Dianthus Therapeutics
DNTH
$5.73B
| – | – |
-80,584
| Closed | -$1.46M |
|
31
CALL
Edgewise Therapeutics
EWTX
$4.23B
| – | – |
-100,000
| Closed | -$2.2M |
|
|
32
Edgewise Therapeutics
EWTX
$4.23B
| – | – |
-102,650
| Closed | -$2.26M |
|
33
Janux Therapeutics
JANX
$959M
| – | – |
-81,292
| Closed | -$2.19M |
|
|
SWTX
34
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-281,139
| Closed | -$12.4M |
|
|
35
Trevi Therapeutics
TRVI
$2.44B
| – | – |
-686,219
| Closed | -$4.32M |
|
36
Tyra Biosciences
TYRA
$1.83B
| – | – |
-107,244
| Closed | -$997K |
|
37
Xenon Pharmaceuticals
XENE
$6.32B
| – | – |
-69,603
| Closed | -$2.34M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q2 2025 Portfolio in Review
As of Q2 2025, Ally Bridge Group held 37 positions worth $120M, up 8.3% from $111M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Ally Bridge Group withdrew a net $7.62M in Q2 2025, closing 13 positions and reducing 5 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $12.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier.
Against the trend, Ally Bridge Group opened a new position in LENZ Therapeutics worth $10.1M.
- Ally Bridge Group's largest Q2 2025 buy was LENZ Therapeutics: 343,322 shares worth $10.1M.
- Ally Bridge Group added most to Soleno Therapeutics in Q2 2025, an estimated $4.37M increase.
- Ally Bridge Group's biggest Q2 2025 reduction was Insmed, cutting an estimated $2.86M.
- Ally Bridge Group fully exited SpringWorks Therapeutics in Q2 2025, selling an estimated $12.4M.
- Ally Bridge Group's ten largest holdings make up 65% of its $120M portfolio in Q2 2025.
- Ally Bridge Group opened 9 new positions and closed 13 in Q2 2025.
- Ally Bridge Group's portfolio value rose 8.3% quarter-over-quarter to $120M.
Based on Ally Bridge Group's 13F filing for Q2 2025, filed 14 Aug 2025.